adorable baby smiling with joy

Peds Calc

Back to Dicloxacillin Overview

Dicloxacillin Indications & Clinical Uses

Evidence-based guide for pediatric prescribing

Dicloxacillin is a penicillinase-resistant oral penicillin used for methicillin-susceptible Staphylococcus aureus (MSSA) infections when culture-directed therapy is required.

Primary FDA-Approved Indications

Prioritize use for confirmed or strongly suspected MSSA skin/soft tissue infections, and transition to oral dicloxacillin only when adherence to q6h dosing is realistic.

Impetigo, ecthyma, or folliculitis caused by MSSA

FDA Approved
Children ≥3 monthsLevel BFirst-line

Use after culture confirmation or in high-likelihood settings (e.g., bullous impetigo). Reinforce hygiene and lesion care.

Treatment Duration

Standard: 7 days (Range: 5–10 days)

Evidence Sources

IDSA SSTI Guideline (2014) ()

Nonpurulent cellulitis or post-I&D MSSA skin infection

FDA Approved
Children and adolescentsLevel BFirst-line

Excellent coverage for MSSA and streptococci. Evaluate adherence barriers; cephalexin is an acceptable alternative if empty-stomach q6h dosing is not feasible.

Treatment Duration

Standard: 7–10 days

Evidence Sources

IDSA SSTI Guideline (2014) ()
Skin and Soft Tissue Infections | AAFP (2015) ()

Secondary Clinical Uses

Step-down therapy for MSSA osteomyelitis or bacteremia

Secondary Use
Level C

Specialist oversight recommended. Ensure reliable oral absorption (empty stomach) and monitor hepatic function and inflammatory markers.

Evidence Sources

Dicloxacillin Sodium Capsules — DailyMed ()

Off-Label Uses

Note: Off-label uses may be clinically appropriate based on evidence and expert consensus, but are not FDA-approved for these indications. Always consider the evidence base and document clinical reasoning.

Osteoarticular MSSA infections (e.g., septic arthritis) after IV therapy

Off-Label
Children under infectious disease supervisionLevel C

Requires close adherence monitoring and periodic lab evaluation (CBC, hepatic function).

Treatment Duration

Standard: 2–4 weeks step-down

Evidence Sources

IDSA Pediatric Osteomyelitis Guidance ()

Clinical Decision Support

Quick Selection Guide

Symptom Cluster 1

Symptoms:

  • Localized erythema
  • Warmth
  • Purulence
  • Culture MSSA

Likely Diagnosis:

MSSA skin/soft tissue infection

Action:

Start dicloxacillin q6h on empty stomach; reassess in 48–72 h

Symptom Cluster 2

Symptoms:

  • Post-op incision
  • Culture-confirmed MSSA
  • Transition from IV therapy

Likely Diagnosis:

MSSA surgical site infection

Action:

Consider dicloxacillin step-down if adherence is reliable

Red Flags & Warnings

History of anaphylaxis to penicillins

Avoid dicloxacillin; consider cephalosporin or non-beta-lactam with allergy consultation

Recurrent boils with MRSA risk

Do not use—select MRSA-active agent

Alternative Medication Options

Cephalexin

First-generation cephalosporin

MSSA infections when q6h empty-stomach dosing is impractical

Advantages
  • Well tolerated
  • Flexible with meals
Disadvantages
  • Broader spectrum than dicloxacillin

Clindamycin

Lincosamide

Penicillin allergy or concern for mixed anaerobic coverage

Advantages
  • Covers some MRSA
Disadvantages
  • Risk of C. difficile

Parent Communication Guide

When This Medicine Helps

Understanding the Condition

Treats skin and other infections caused by penicillin-resistant staph bacteria (MSSA).

Why We Choose This Medicine

This antibiotic prevents the bacteria from making cell walls so your child’s immune system can clear the infection.

What to Expect

Improvement in 48–72 hours; complete the full course to prevent relapse.

Monitoring Your Child

Signs the Medicine is Working:

  • Less redness and swelling
  • Lower fever
  • Pain improves

When to Contact Your Doctor:

No improvement after: No change after 72 hours or new fever

Watch for these warning signs:

  • Spreading redness
  • Signs of allergy
  • Inability to keep doses down
Last updated: 9/24/2025
Back to Overview